N/A N=22 Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
Overactive Detrusor
Primary: Mean Peak Detrusor Pressures — 58; 31 cm H2O
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
Early Phase 1 N=4 High Frequency SARS for Neurogenic Bladder and Bowel Emptying
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
Phase 2 N=37 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
N/A N=12 Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
Multiple Sclerosis · Lower Urinary Tract Symptoms · Neurogenic Bladder
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment — 2.6; 2.6; 3.5; 2.6 BOLD Signal Change Derived T-Value — p=0.0012
N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
Phase 3 N=20 Effect of Tizanidine on Postoperative Urinary Retention After Sacrospinous Suspension
Postoperative Urinary Retention · Sacrospinous Vaginal Vault Suspension · Reconstructive Pelvic Surgery
Primary: Number of Participants With Postoperative Urinary Retention — 11 Participants
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 3 N=87 An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary Incontinence
Primary: Number of Leaks Per Day — NA; NA Number of Leaks Per Day
Phase 3 N=386 Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Urinary Incontinence, Urge
Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes
Phase 4 N=168 Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
Urgency Urinary Incontinence
Primary: Responder (Yes/no) — 23; 39; 36; 17 Participants
N/A N=50 Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
Chronic Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Reduction in Bladder Medication — 19; 15 Participants
Phase 3 N=416 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes
N/A N=31 Comparison of Motor and Sensory Response With Interstim Stimulation
Overactive Bladder · Urgency-Frequency
Primary: Percent of Symptoms With Improvement of Leaks Reported — 14.4; 19.8; 18.2 Percent change in leaks
N/A N=21 Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Phase 4 N=24 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
Detrusor Hyperreflexia
Primary: Average Number of Catheterizations Without Leaking Per Day — 2.4; 1.5 Number of Dry Catheterizations per Day
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
N/A N=55 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Urinary Incontinence
Primary: Change From Baseline in Anticholinergic Drug Use — 305.21; 199.77 Doses of Anticholinergic Drugs
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 2 N=22 Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients
Stress Urinary Incontinence
Primary: Change From Baseline in Opening Urethral Pressure (OUP) at Day 7 — 49.86; 49.86; 49.86; 47.92 centimeter of water (cmH2O) — p=0.4907